Correction to: Signal Transduction and Targeted Therapy (2024) 9:327; 10.1038/s41392-024-02058-x; Article published online 20 November 2024
After the online publication of the research highlight,1 a reader pointed out that the MVA vaccine used in the original study by Mucker et al.2 was mistakenly labeled as “Jynneos”. The authors have now pointed out in the text, that the comparator vaccine used in the original study was the MVA-572 strain and not the MVA-BN (Jynneos) vaccine. The explanations “vaccine study” and “mpox virus challenge” were added to the first panel of Fig. 1 to clarify the study design. In the lower panel, the antibody functions were provided in more detail to avoid misunderstanding by the readers. The corrected figure is provided below. The main messages of this research highlight are not affected by these corrections.
Incorrect Figure
Correct Figure
The original article has been corrected.
Contributor Information
Leonie Mayer, Email: l.mayer@uke.de.
Leonie M. Weskamm, Email: m.weskamm@uke.de
References
- 1.Mayer, L., Weskamm, L. M. & Addo, M. M. Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates. Signal Transduct. Target. Ther.9, 1–3 (2024). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Mucker, E. M. et al. Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates. Cell187, 5540–5553.e10 (2024). [DOI] [PubMed] [Google Scholar]